CPIX (Cumberland Pharmaceuticals) Total Receivables: $14.26 Mil (As of Mar. 2026)


CPIX Cumberland Pharmaceuticals Inc CPIX
32 GF Score
Price $6.75
GF Value $2.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cumberland Pharmaceuticals Total Receivables?

Cumberland Pharmaceuticals CPIX +12.50% 32 Total Receivables is $14.26 Mil as of Mar. 2026. GuruFocus rates CPIX with a GF Score™ of 32/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Cumberland Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was $14.26 Mil.

Cumberland Pharmaceuticals Total Receivables Related Terms

Cumberland Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Cumberland Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cumberland Pharmaceuticals Total Receivables Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.88 13.16 9.76 11.70 16.95

Cumberland Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.49 10.32 10.43 16.95 14.26
CPIX
32GF Score
Cumberland Pharmaceuticals Inc CPIX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cumberland Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $14.26 Mil mean?
Cumberland Pharmaceuticals (CPIX) has a Total Receivables of $14.26 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cumberland Pharmaceuticals and its competitors.
Is Cumberland Pharmaceuticals' Total Receivables too high?
Cumberland Pharmaceuticals' current Total Receivables is $14.26 Mil. Overall, Cumberland Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Total Receivables compare to CTOR and INCR?
Cumberland Pharmaceuticals' Total Receivables of $14.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cumberland Pharmaceuticals and its competitors. Cumberland Pharmaceuticals's current Total Receivables is $14.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.75 — trading 212.5% above its estimated fair value. The current Total Receivables is $14.26 Mil. Cumberland Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Total Receivables is $14.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued. The current stock price of $6.75 is trading 212.5% above its estimated GF Value™ of $2.16. GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CPIX:

  • Total Receivables: $14.26 Mil
  • GF Value™: $2.16 vs. price of $6.75 (212.5% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cumberland Pharmaceuticals Business Description

Address 1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
32GF Score

Get the complete analysis for CPIX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75
Price
$2.16
GF Value